移植后环磷酰胺扩增功能性髓源性抑制细胞并间接影响调节性T细胞
在主要组织相容性复合体单倍体相合小鼠造血细胞移植模型中,移植后第+3天和第+4天给予环磷酰胺可扩增具有抑制功能的粒系和单核系髓源性抑制细胞,并迅速促进骨髓前体细胞生成髓源性抑制细胞;清除髓源性抑制细胞虽不加重组织病理学移植物抗宿主病,但导致调节性T细胞减少和生存期缩短。接受HLA单倍体相合移植的患者给予环磷酰胺后髓源性抑制细胞比例也升高。
要点
- 小鼠单倍体相合移植模型中,第+3、+4天给予环磷酰胺可扩增功能性粒系和单核系髓源性抑制细胞。
- 抗Gr1清除髓源性抑制细胞不加重组织病理学移植物抗宿主病,但调节性T细胞减少、生存期缩短。
- 接受HLA单倍体相合移植的患者给予环磷酰胺后髓源性抑制细胞比例升高。
核心结论
- 移植后环磷酰胺对调节性T细胞的影响看似间接,髓源性抑制细胞可能发挥互补作用。
- 移植后环磷酰胺扩增的髓源性抑制细胞对植入和细胞因子释放综合征的潜在影响尚待阐明。
- 移植后环磷酰胺对调节性T细胞的间接作用需进一步研究。
研究设计与样本
- 研究采用T细胞充足的主要组织相容性复合体单倍体相合小鼠造血细胞移植模型(B6C3F1→B6D2F1)。
- 研究涉及接受HLA单倍体相合造血细胞移植并给予移植后环磷酰胺的患者。
主要发现
- 在移植后环磷酰胺处理小鼠中,清除初始移植物而非第+5天脾细胞中的Foxp3+调节性T细胞未加重移植物抗宿主病。
- 同时清除两个细胞区室的调节性T细胞后,第+5天脾细胞诱导了致死性移植物抗宿主病。
- 移植后环磷酰胺处理小鼠中功能性抑制性粒系和单核系髓源性抑制细胞百分比升高。
- 接受HLA单倍体相合移植的患者给予移植后环磷酰胺后髓源性抑制细胞百分比升高。
- 移植后环磷酰胺增加对髓源性抑制细胞发育关键的集落刺激因子,并迅速促进骨髓前体细胞生成髓源性抑制细胞。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 移植后环磷酰胺扩增的髓源性抑制细胞对植入和细胞因子释放综合征的潜在临床影响尚待阐明。
- 移植后环磷酰胺对调节性T细胞的间接作用需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Posttransplantation cyclophosphamide (PTCy), given on days +3 and +4, reduces graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT), but its immunologic underpinnings are not fully understood. In a T-cell-replete, major histocompatibility complex-haploidentical murine HCT model (B6C3F1→B6D2F1), we previously showed that PTCy rapidly induces suppressive mechanisms sufficient to prevent GVHD induction by non-PTCy-exposed donor splenocytes infused on day +5. Here, in PTCy-treated mice, we found that depleting Foxp3+ regulatory T cells (Tregs) in the initial graft but not the day +5 splenocytes did not worsen GVHD, yet depleting Tregs in both cellular compartments led to fatal GVHD induced by the day +5 splenocytes. Hence, Tregs were necessary to control GVHD induced by new donor cells, but PTCy's impact on Tregs appeared to be indirect. Therefore, we hypothesized that myeloid-derived suppressor cells (MDSCs) play a complementary role. Functionally suppressive granulocytic and monocytic MDSCs were increased in percentages in PTCy-treated mice, and MDSC percentages were increased after administering PTCy to patients undergoing HLA-haploidentical HCT. PTCy increased colony-stimulating factors critical for MDSC development and rapidly promoted the generation of MDSCs from bone marrow precursors. MDSC reduction via anti-Gr1 treatment in murine HCT did not worsen histopathologic GVHD but resulted in decreased Tregs and inferior survival. The clinical implications of these findings, including the potential impact of expanded MDSCs after PTCy on engraftment and cytokine release syndrome, remain to be elucidated. Moreover, the indirect effect that PTCy has on Tregs, which in turn play a necessary role in GVHD prevention by initially transplanted or subsequently infused T cells, requires further investigation.
引用
- Fletcher RE, Nunes NS, Patterson MT, et al. Posttransplantation cyclophosphamide expands functional myeloid-derived suppressor cells and indirectly influences Tregs. Blood Adv. 2023. PMID: 36595377. doi:10.1182/bloodadvances.2022007026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。